A series of cardiometabolic-related news items has been observed from Whoop, Currax Pharmaceuticals, Novo Nordisk, and Ambrosia Biosciences. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Inventiva, Beta Bionics, and Vaxess Technologies. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Kailera Therapeutics, Diamyd Medical, Insilico, Bayer, Gan & Lee Pharmaceuticals, Roche, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Kailera, and Ionis Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Wave Life Sciences announced updated data from its Ph1 INLIGHT study of WVE-007 in obesity (view press release); Novo Nordisk hosted its 2026 Annual General Meeting (view notice); and Viking Therapeutics completed enrollment for its Ph3 VANQUISH-2 study of VK2735 (view press release). Below, FENIX provides highlights and insights from the respective news items.
A series of cardiometabolic-related news items has been observed by Novo Nordisk, Boehringer Ingelheim, Pfizer, Merck, Fractyl Health, Biomea Fusion, and BrightGene Bio-Medical Technology. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed by Zealand Pharma, Aardvark Therapeutics, Rezolute, and Rivus Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
Three cardiometabolic-related news items have been observed: Lexicon Pharmaceuticals and Novo Nordisk initiated a Ph1 obesity study of its oral ASCL5 inhibitor (view press release); FDA shared plans to host a public feedback meeting regarding the CNPV pilot program (view press release); and the CHMP agenda for this month’s meeting (March 23-26) has been released (view agenda). Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Novo Nordisk has initiated its Ph3 AMAZE 5 study of zenagamtide in knee OA (view CT.gov record); and Biohaven announced it completed enrollment for its Ph2b POC study evaluating QW and QM formulations of taldefgrobep alfa (view press release). Below, FENIX provides highlights and insights on the respective news items, including thoughts on Novo’s decision not to conduct AMAZE 5 H2H vs. tirzepatide.
Three cardiometabolic-related news items have been observed: MiniMed Flex received FDA clearance and launched its MiniMed Forward Program (view press release); MetaVia received IRB approval to advance DA-1726 in obesity (view press release); and Ascletis Pharma selected its oral amylin ASC39 as its next obesity candidate (view press release). Below, FENIX provides highlights and insights for the respective news items.